Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-06079-y
Abstract: Does the presence of POD24 serve as a reliable prognostic factor for adverse outcomes in all individuals diagnosed with B-cell indolent lymphoma? The interrelationship between POD24 and these prognostic assessment tools. The pathogenesis of early… read more here.
Keywords: indolent cell; prognosis; cell; pod24 ... See more keywords
Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-201078
Abstract: Background: Approximately20% of patients with follicular lymphoma (FL) will experience disease progression or death within two years of years (POD24) of immunochemotherapy (IC) (Casulo et al, JCO 2015). A proportion of patients with POD24 have… read more here.
Keywords: histology; biopsy; pod24; lymphoma ... See more keywords
Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3576
Abstract: Mantle cell lymphoma (MCL) is characterized by biological and clinical heterogeneity ranging from an indolent to highly aggressive lymphoma. Although prognosis is improving, prolonged impairment of quality-of-life due to treatments remain significant concerns, calling for… read more here.
Keywords: mcl; cohort; cell lymphoma; protein adamts8 ... See more keywords
Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020010263
Abstract: Observational studies and standalone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical… read more here.
Keywords: analysis; evaluated association; pod24; poor survival ... See more keywords
Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e19057
Abstract: e19057 Background: In ELM-2 (NCT03888105), a Ph 2, single arm, open label trial, odronextamab demonstrated robust efficacy, generally manageable safety, and overall maintenance of patient-reported outcomes (PROs) in R/R FL pts (Villasboas et al. ASH… read more here.
Keywords: pod24 status; hrqol functioning; functioning symptoms; pod24 ... See more keywords
Nomograms to predict progression of disease within 24 months in patients with localized natural killer/T-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0307
Abstract: Aims: Progression of disease within 24 months (POD24) is associated with poor survival in some subtypes of lymphoma.The aim is to identify high-risk patients with localized extranodal natural killer/T-cell lymphoma (ENKTL) and to define clinical factors… read more here.
Keywords: oncology; pod24; within months; progression disease ... See more keywords